xmlns="http://www.w3.org/2000/svg" viewBox="0 0 54 54">
Gå til indhold
English

Årsag til vaccination, flokimmunitet

Her på siden har vi samlet viden, så du kan læse mere om flokimmunitet, og hvordan den udregnes.

Beregning af flokimmunitet

I Sundhedsstyrelsens notat vedrørende vaccination af 12-15 årige kan du læse mere om flokimmunitet og beregninger for estimeret immunitet i befolkningen fra side 27:

Læs Sundhedsstyrelsens notat vedr. vaccination af 12-15 årige

Studier der i notat henvises til i forbindelse med udregning af flokimmnunitet:

I Sundhedsstyrelsens notat Vedrørende vaccination af 12-15 årige henvises i afsnittet om flokimmunitet til studier, der vedrører flokimmunitet, bl.a. om beregninger af immunitet i befolkningen og den beskyttende effekt af vacciner. Find mere viden i studierne:

  • Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020 May 19;52(5):737- 741.
  • Anderson, R., May, R. Vaccination and herd immunity to infectious diseases. Nature 318, 323–329 (1985).
  • Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020 May 19;52(5):737- 741.
  • Fine P, Eames K, Heymann DL. “Herd Immunity”: A Rough Guide. Clin Infect Dis. 2011 Apr 1;52(7):911-
  • Rahman B, Sadraddin E, Porreca A. The basic reproduction number of SARS-CoV-2 in Wuhan is about to die out, how about the rest of the World?. Rev Med Virol. 2020;30(4):e2111. 
  • Statens Serum Institut. Kontakttal for virusvariant B.1.1.7. Ekspertgruppen d. 3. februar 2021. Københavns: SSI; 2021: https://covid19.ssi.dk/-/media/cdn/files/kontakttal-for-b117-d-3-februar-2021_04022021.pdf?la=da Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing transmissibility of SARSCoV-2 lineage B. 1.1. 7 in England. Nature. 2021;593(7858):266-9.
  • Davies NG, Abbott S, Barnard RC et al.Estimated transmissibility and impact of SARS-CoV-2 lineage 
    B.1.1.7 in England. Science. 2021 Apr 9;372(6538):eabg3055. https://covid19.ssi.dk/virusvarianter/virusvariantbeskrivelser
  • Hodgson D, Flasche S, Jit M et al. The potential for vaccination-induced herd immunity against the SARSCoV-2 B.1.1.7 variant. Euro Surveill. 2021;26(20):pii=2100428.
  • Petter E, Mor O, Zuckerman N et al. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. medRxiv doi: https://doi.org/10.1101/2021.02.08.21251329
  • Jones NK, Rivett L, Seaman S et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARSCoV-2 infection. Elife. 2021 Apr 8;10:e68808.
  • McEllistrem MC, Clancy CJ, Buehrle DJ. Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19. Clin Infect Dis. 2021 Mar 26:ciab263.
  • Levine-Tiefenbrun M, Yelin I, Katz R et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021 May;27(5):790-792.
  • Milman O, Yelin I, Aharony N et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nat Med. 2021 Jun 10. [Epub ahead of print]
  • Tande AJ, Pollock BD, Shah ND, et al. Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular. Clin Infect Dis. 2021;ciab229. 
  • Tang L, Hijano DR, Gaur AH, et al. Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA. Published online May 06, 2021. 
  • Haas EJ, Angulo FJ, McLaughlin JM et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021 May 15;397(10287):1819-1829. 
  • Angel Y, Spitzer A, Henig O, et al. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. JAMA. Published online May 06, 2021. 
  • Hall VJ, Foulkes S, Saei A et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021 May 8;397(10286):1725-1735. 
  • Lustig Y et al. 2021. Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2, DOI: 10.1056/NEJMc2104036 
  • Yang L et al. 2021. Neutralizing Activity of BNT162b2-Elicited Serum. DOI: 10.1056/NEJMc2102017. Kai W et al. 2021. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. bioRxiv preprint doi: 10.1101/2021.04.13.439482 
  • Bernal JL, Andrews N, Gower C et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv 2021.05.22.21257658 doi: https://doi.org/10.1101/2021.05.22.21257658
     
Opdateret 19 AUG 2021